Hikma agrees $50m settlement for Xyrem class actions
said on Thursday that it has entered into a preliminary $50m class settlement agreement that resolves the majority of its Xyrem (sodium oxybate) antitrust class action cases in the US.
The settlement relates o lawsuits brought against the company by third-party payors in the US who have purchased or been billed for Xyrem, a medication used to treat narcolepsy.
Sam Park, Hikma's General Counsel, said: "We are pleased to have reached a settlement agreement that protects the company's interests and provides clarity to our stakeholders.
"We are proud to have facilitated patients' access to a lower-cost authorised generic version of this essential medicine, years ahead of its patent expiration."
Hikma said that the settlement - which is subject to court approval - is not an admission of wrongdoing or liability, and that it will continue to defend itself "vigorously" against any litigation that this settlement does not resolve.
At 1040 BST, the shares were up 0.2% at 2,008p.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.